Lupin

Sun Pharma and Lupin’s US operations face a setback as they recall products from the market, impacting operations and potentially disrupting patient care.

Sun Pharma and Lupin, two major pharmaceutical companies in India, have initiated a voluntary recall of several products from the US market. The recall was initiated by the US Food and Drug Administration (FDA) due to alleged concentration variations in some lots of their products.

Sun Pharma, one of the largest generic drug makers in the world, has recalled 14 products due to the presence of a potential issue in their manufacturing process. The recalled products, including anti-inflammatory, anti-diabetic, and antibiotic treatment medications, were manufactured at one of Sun Pharma’s facilities in India. The company is recalling these products from the US market to ensure that patients receive high-quality medicines.

Lupin, another leading Indian generic drug maker, has also initiated a recall of 24 products due to a potential manufacturing issue. The recalled products include treatments for high blood pressure, cholesterol, and respiratory conditions. The FDA has identified a quality product deviation in some lots of these products, which may have resulted in incorrect concentrations of active pharmaceutical ingredients.

In both cases, the affected products are being recalled to ensure that patients receive the correct doses of medication and to prevent any potential harm. The FDA is working closely with both companies to ensure that the recalled products are removed from the market and that appropriate corrective actions are taken to prevent similar issues in the future.

The recalls are a testament to the importance of robust quality control measures in pharmaceutical manufacturing. The FDA’s vigilance in identifying potential issues and working with companies to correct them helps to ensure the safety and efficacy of medications in the US market. The recalls are also a reminder to consumers and healthcare professionals to stay vigilant and report any concerns about the quality or effectiveness of medications to the FDA.

Overall, the recalls highlight the need for pharmaceutical companies to maintain high-quality manufacturing standards and for healthcare professionals to be aware of potential issues with certain products. As the demand for affordable and effective medications continues to grow, it is essential for pharmaceutical companies to prioritize quality and for regulatory agencies to closely monitor and address any potential issues.

Lupin experiences continued growth in the US market thanks to the success of new product launches and a robust pipeline of upcoming offerings.Note that I used the same meaning and sentence structure, but reworded the sentence to make it more concise and natural-sounding. I also used more formal language, as the original sentence appears to be a PR or business announcement.

Lupin, a leading player in the Indian pharmaceutical industry, is reporting strong performance in certain segments such as diabetes and neurology, despite facing some pressure on its respiratory products portfolio. The company’s Indian business is continuing to perform well, driven by the growth of segments such as diabetes and neurology, while its European business saw a 20% growth, led by strong performances in Germany and the UK.

However, Lupin is also facing some headwinds in the respiratory segment, which is being addressed through the introduction of new, differentiated products. The company is ramping up its investments in research and development, with a focus on complex injectables and biosimilars, which are expected to be a significant opportunity in the market.

To drive margin expansion, Lupin is also focusing on cost optimization, scrutinizing every cost element, from raw materials to vendor development. This disciplined approach has helped improve the company’s profitability.

Despite some challenges in the short term, Lupin is confident of sustaining its double-digit growth trajectory over the next two to three years. The company believes that its solid pipeline, continued growth in India and Europe, and disciplined approach to cost control will enable it to achieve this goal. Overall, the company is optimistic about its future prospects, with the potential for topline buoyancy across all its key markets, driven by new products and lower price erosion on some of its in-line products.

Lupin Reports Strong Q3 Performance, Offloads OTC Portfolio Amid Continued Growth

Pharmaceutical company Lupin has announced that it will be transferring its over-the-counter (OTC) consumer healthcare business to a wholly-owned subsidiary, valued at between ₹550 crore and ₹650 crore. The company reported strong financial results for the third quarter, with a profit after tax of ₹858 crore, a 38.8% increase from the previous year, and sales of ₹5,618 crore, a 10.6% rise. The company’s OTC business revenue was ₹148 crore in FY24, accounting for approximately 1% of its standalone turnover.

Lupin’s Managing Director, Nilesh Gupta, attributed the company’s strong performance to its continued growth in the US market, driven by the scaling up of new products and robust results from the India and EMEA regions. The company has also secured six abbreviated new drug approvals (ANDA) in the US and launched two new products during the quarter.

The company plans to finalize the Business Transfer Agreement (BTA) by April 30, 2025, or as mutually agreed, and complete the transaction by June 30, 2025. With the OTC business separate from its core prescription drugs, Lupin can focus on its strengths in the prescription drug market. The company’s decision to transfer the OTC business is intended to position it for further growth in the rapidly expanding OTC market.

Lupin’s North American sales for the quarter reached ₹2,121 crore, a 12.3% increase, and accounted for 38% of its global sales. The company’s presence in the US market has strengthened with 163 generic products launched.

Lupin Reports Financial Results for Q3 of Fiscal Year 2025

Here is a summary of the content in 400 words:

Lupin, a global pharmaceutical leader, has reported its quarterly financial results for Q3 FY2025. The company’s sales for the quarter stood at INR 62,457 Mn, up 12.3% compared to the same period last year. The company has a strong presence in various markets, including North America, India, Europe, Middle East, and Africa (EMEA), and Emerging Markets (APAC and LATAM).

In North America, Lupin’s sales stood at INR 21,213 Mn, up 12.3% year-on-year, accounting for 38% of the company’s global sales. The company received six ANDA approvals from the US FDA and launched two products in the quarter, taking its total number of generics products in the US to 163. Lupin continues to maintain its leadership position as the third-largest pharmaceutical player in the US generics market and total market by prescriptions.

In India, the company’s formulation sales stood at INR 19,305 Mn, up 12% year-on-year, accounting for 34% of its global sales. The company launched 11 new brands across various therapy areas during the 9M period. Lupin is the seventh-largest company in the Indian pharmaceutical market.

In EMEA, the company’s sales stood at INR 6,249 Mn, up 21% year-on-year, accounting for 11% of its global sales. In Emerging Markets, the company’s sales were down 4.7% year-on-year, accounting for 8% of its global sales.

The company’s research and development (R&D) investment during the quarter stood at INR 4,344 Mn, accounting for 7.7% of its sales. Lupin received approval for six ANDA filings from the US FDA during the quarter, taking its total number of filings to 430. The company has 49 first-to-file (FTF) filings, including 17 exclusive FTF opportunities, and 156 DMF filings.

Overall, Lupin is a leading global pharmaceutical company with a strong presence in various markets, and is committed to improving patient health outcomes through its subsidiaries Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Lupin’s Global Chief Financial Officer Warns that Trump’s Tariffs Could Leave Many Americans Without Access to Life-Saving Medications

Here is a 400-word summary of the content:

Lupin, a global pharmaceutical company, is warning that the ongoing trade tensions and tariffs imposed by the Trump administration could lead to a shortage of life-saving medicines in the United States. According to Global Chief Financial Officer KBuildalp, the tariffs could have devastating consequences, denying many Americans access to essential medicines.

The company is particularly concerned about the tariffs on active pharmaceutical ingredients (APIs), which are used in the production of many medicines. APIs are imported from countries like India, where Lupin is based, and China. The tariffs imposed on these imports are increasing costs, making it challenging for pharmaceutical companies like Lupin to maintain their competitiveness in the market.

Lupin’s CFO warned that if the tariffs continue, it could lead to a shortage of critical medicines, including those used to treat cancer, diabetes, and heart disease. This could have significant human consequences, as patients may not have access to the medication they need to manage their conditions and stay healthy.

The company is not alone in its concerns. Other pharmaceutical companies and industry associations have also spoken out against the tariffs, citing the risks to patient access to life-saving treatments. The sector is urging the Trump administration to reconsider its tariff policy and work with India and China to find a peaceful solution.

Lupin’s concerns are echoed by the World Health Organization (WHO), which has warned that the tariffs could have a significant impact on global health. The organization is urging countries to prioritize patient access to essential medicines and negotiate fair and transparent trade agreements that do not compromise public health.

In conclusion, the tariffs imposed by the Trump administration could have severe consequences for patients in the United States, including a shortage of life-saving medicines. Lupin and other pharmaceutical companies are urging the administration to reconsider its policy and work towards a solution that prioritizes patient access to essential treatments. The WHO has also sounded the alarm, warning that the tariffs could have significant negative impacts on global public health.

Lupin and Natco gain U.S. FDA approval for their generic bosentan suspension

Here is a 400-word summary of the article:

Lupin and Natco Pharmaceuticals have announced that their jointly developed generic version of bosentan suspension, used to treat pulmonary arterial hypertension (PAH), has received approval from the US Food and Drug Administration (FDA). This approval makes the companies’ product the first FDA-approved generic alternative to Pfizer’s branded treatment, Tracleer.

The bosentan suspension is indicated for the treatment of PAH, a rare and chronic respiratory condition characterized by abnormally high blood pressure in the pulmonary arteries. The medication is used to delay disease progression and improve exercise capacity in patients with PAH.

Lupin and Natco’s generic version of bosentan suspension has been demonstrated to be therapeutically equivalent to Tracleer, which means it has the same efficacy, safety, and dosage regimen as the branded product. The approval is based on a comprehensive regulatory submission package, which included results from clinical trials that evaluated the safety and efficacy of the generic product in comparison to Tracleer.

“This FDA approval marks a significant milestone for us and further reinforces our commitment to delivering high-quality generic products that make a meaningful difference in patients’ lives,” said Vinita Gupta, Managing Director, Lupin.

The approval is a significant win for Lupin and Natco, as it opens up the PAH market to more affordable treatment options. PAH is a rare condition that affects an estimated 150,000 people in the US, and there is a high demand for treatments that can slow down disease progression.

The availability of a generic bosentan suspension is expected to benefit patients by providing a more affordable alternative to the branded treatment. This will not only increase patient access to treatment but also reduce the financial burden on healthcare systems.

The companies are set to launch their generic product in the US market shortly, making it the first FDA-approved generic alternative to Tracleer. With this approval, Lupin and Natco have demonstrated their capabilities to develop and launch high-quality generic products that can effectively compete with branded treatments in the US market.

Miralus, a collaboration between Lupin and Natco, receives US FDA approval for its generic Bosentan tablets for oral suspension, expanding access to vital hypertensive treatment options.

Natco Pharma, in alliance with Lupin, has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Bosentan Tablets for Oral Suspension, 32 mg, a generic equivalent of Actelion Pharmaceuticals’ Tracleer Tablets for Oral Suspension. With this approval, Natco becomes the first company to file for the product in the US, granting it 180 days of marketing exclusivity. The generic drug is used to treat pediatric patients with idiopathic or congenital pulmonary arterial hypertension (PAH), helping to improve pulmonary vascular resistance and exercise ability. The estimated annual sales of Tracleer, the reference listed drug, are USD 11 million in the US, based on IQVIA MAT data from December 2024.

Bosentan Tablets for Oral Suspension, 32 mg, is specifically indicated for children aged three and above with idiopathic or congenital PAH. The medication aims to lower pulmonary vascular resistance, which improves exercise ability and quality of life for patients affected by this rare and debilitating disease. With the approval of this generic equivalent, Natco Pharma will be the sole supplier of the product for the next six months, gaining a competitive edge in the US market.

Natco’s ANDA approval underscores the company’s commitment to offering high-quality generic alternatives to brand-name drugs. The company has successfully navigated the FDA approval process, ensuring that its generic product meets stringent standards for quality, safety, and efficacy. The approval is expected to make Bosentan Tablets for Oral Suspension, 32 mg, more accessible and affordable for pediatric patients with PAH, leading to improved patient outcomes and increased access to vital medication.

Lupin Names Abdelaziz Toumi as CEO of its API CDMO Subsidiary

Lupin, a global pharmaceutical company, has appointed Abdelaziz Toumi as the Chief Executive Officer (CEO) of its API (Active Pharmaceutical Ingredient) CDMO (Contract Development and Manufacturing Organization) subsidiary. The appointment is effective immediately.

Toumi brings over 25 years of experience in the pharmaceutical industry, with a strong background in API development, manufacturing, and commercialization. He has held various leadership positions in companies such as Novartis, Roche, and most recently, as the Head of API Manufacturing at Lonza.

As the CEO of Lupin’s API CDMO subsidiary, Toumi will be responsible for leading the company’s API development and manufacturing capabilities, including the production of complex and highly potent APIs. He will also oversee the commercialization of these APIs, working closely with Lupin’s global customers and partners.

Toumi’s appointment is seen as a strategic move by Lupin to strengthen its API capabilities and expand its presence in the CDMO market. The company has been investing heavily in its API development and manufacturing capabilities, and Toumi’s expertise will help drive this growth.

Lupin’s API CDMO subsidiary offers a range of services, including API development, manufacturing, and packaging, as well as regulatory support and quality control. The company serves a diverse range of customers, including pharmaceutical companies, biotechnology firms, and research institutions.

In a statement, Lupin’s Managing Director, Vinita Gupta, welcomed Toumi to the company and expressed her confidence in his ability to lead the API CDMO subsidiary to success. “Abdelaziz brings a wealth of experience and expertise to Lupin, and we are excited to have him on board,” she said. “His leadership will be instrumental in driving the growth and success of our API CDMO business.”

Toumi’s appointment is seen as a significant development in the pharmaceutical industry, as it highlights the growing importance of API development and manufacturing capabilities. The appointment also underscores Lupin’s commitment to investing in its API business and expanding its presence in the CDMO market.

Does Lupin’s financial profile reveal a balanced sheet?

Lupin Limited, a pharmaceutical company, has a debt-to-equity ratio of 0.056, which is considered low. The company’s balance sheet shows that it has liabilities of ₹79.9 billion due within 12 months and liabilities of ₹17.7 billion due beyond that. However, it also has cash and receivables of ₹29.1 billion and ₹51.6 billion, respectively, which offsets its liabilities. This means that Lupin’s balance sheet looks solid, with its total liabilities being almost equal to its liquid assets.

Lupin’s debt-to-EBITDA ratio is 0.056, which is very low. Additionally, the company’s EBIT has grown by 91% over the last 12 months, making it easier for it to handle its debt. However, the company’s cash conversion ratio is weaker than expected, with only 31% of its EBIT being matched by actual free cash flow. This makes it more difficult for Lupin to handle its debt.

Despite these concerns, Lupin’s interest cover suggests that it can handle its debt easily. The company’s debt is also not a concern as it is well-covered by its cash and liquid assets. The company’s use of debt seems reasonable, and it can bring a higher return on equity when used wisely.

Overall, Lupin’s balance sheet looks solid, and its use of debt seems reasonable. However, investors should keep an eye on the company’s cash conversion ratio and its ability to generate free cash flow to ensure that it can handle its debt obligations.

Sun Pharma to fork out a record Rs 1,602 crore penalty, after emerging as the top company in a list of six major pharma firms currently under tax scanner.

Sun Pharma, one of India’s largest drug manufacturers, has been directed to pay a penalty of Rs 1,602 crore (approximately $220 million) to the Indian government. This comes as part of a broader crackdown on tax evasion by several top drug companies in the country. According to a report, the company’s tax demand was made following an investigation by theIncome Tax (I-T) department, which found irregularities in the company’s tax returns.

Sun Pharma is just one of six major drug companies being targeted in the tax scrutiny, which is a significant move by the government to crack down on tax evasion. The other companies include Dr. Reddy’s Laboratories, Lupin Ltd, Cadila Healthcare, Cipla Ltd, and Glenmark Pharmaceuticals. All of these companies are among the top 10 drug makers in the country.

The crackdown is based on alleged violations of the Income Tax Act, the Companies Act, and other laws. The I-T department claims that these companies had understated their taxable income by reclassifying revenues, misstating expenditure, and manipulating accounts. The tax authority has also accused them of failing to disclose information on loan transactions, capital gains, and foreign exchange earnings.

The I-T department’s action is a major development in the country’s pharmaceutical industry, which has been reeling from the impact of recent regulatory changes and tough competition from generic drug makers. While the exact timing of the tax demand is unclear, it is widely believed to be in response to a hint given by the government in 2019 that it would become stricter in enforcing tax laws.

It is worth noting that the companies have the right to appeal against the tax demand and the I-T department’s findings. While some of these companies have already appealed, others have chosen to contest the demand through legal means. The outcome of this high-stakes battle will be keenly watched by investors, taxpayers, and the pharmaceutical industry as a whole.

Lupin Experiences Strong Q2 FY24-25 Profit Uptick Amid Ongoing Challenges and Uncertainty

Here is a summary of the content in 400 words:

Lupin, a leading pharmaceutical company, has reported a significant profit growth in its second quarter of FY24-25, driven by operational efficiency improvements and cost control measures. However, the company faces long-term growth challenges due to the ongoing impact of the COVID-19 pandemic, intense competition, and pressures from regulatory changes.

In the second quarter, Lupin reported a profit growth of 15.1% to ₹923.6 crores, which is significantly higher than the market expectations. The company’s profit was driven by a 12.2% reduction in operating expenses, which enabled it to maintain its profitability despite the challenging market conditions.

The company’s revenue, however, declined 12.6% to ₹2,334.5 crores due to the ongoing COVID-19 pandemic, which has affected the demand for generic medicines. The company’s sales were also impacted by the regulatory changes, including the introduction of price caps on certain medicines by the National Pharmaceutical Pricing Authority (NPPA).

Lupin is taking steps to overcome these challenges, including expanding its presence in high-growth markets, developing new products, and improving its operational efficiency. The company is also exploring opportunities in the biotechnology and biosimilar segment, which are expected to drive long-term growth.

In the short term, however, Lupin is bracing for a challenging market environment, which is expected to continue until the COVID-19 pandemic is brought under control. The company’s gross margin is expected to remain under pressure, driven by the regulatory changes and the impact of the pandemic on the demand for its products.

Despite the short-term challenges, Lupin’s long-term prospects remain positive, driven by its focus on innovation, operational efficiency, and strategic expansion into new markets. The company’s strong cash reserves and low debt levels also provide it with the flexibility to invest in new initiatives and navigate the challenging market conditions.

Overall, while Lupin’s short-term performance is expected to be impacted by the COVID-19 pandemic and regulatory changes, the company’s long-term growth prospects remain strong, driven by its focus on innovation and strategic expansion.

Lupin Records 6.7% Net Profit Growth, Eighth Straight Quarter of Consistent Performance

Here is a summary of the content in 400 words:

Lupin, a major Indian pharmaceutical company, has announced its quarterly earnings results, revealing a net profit growth of 6.7%. This significant increase marks the company’s eighth consecutive quarter of net profit gains, solidifying its position in the pharmaceutical industry. The results have exceeded analyst expectations, prompting optimism about Lupin’s continued growth and stability.

According to the report, Lupin’s total income stood at Rs. 5,346.1 crores, representing a rise of 15.6% over the corresponding period last year. The net profit of the company during this period stood at Rs. 833.7 crores, marking a year-on-year (YoY) growth of 6.7%. Lupin’s consolidated financial performance is strong, driven primarily by its innovative medicines business.

Lupin’s Chairman and Managing Director, Nilesh Gupte, commented on the quarterly results, attributing the strong performance to the company’s ongoing efforts to focus on quality and cost-effective research and development, as well as strategic investments in key areas of growth. “Our results for the quarter and half year reinforce our confidence in the strategy we have pursued in recent years. We are encouraged by the sustained momentum we see across our geographies, driven by the efforts of our people,” he added.

Lupin has maintained its leadership in the pharmaceutical market through a commitment to delivering innovative products and quality patient care. The company continues to focus on building a portfolio of high-margin, niche medicines and developing expertise in specialized therapies such as gastroenterology and pain management. Its expanding global footprint and expanding partnerships are expected to further contribute to the company’s growth momentum.

With Lupin’s ongoing growth trajectory and increasing competitiveness, analysts and investors alike are expressing optimism about the company’s potential to sustain this growth pace over the coming periods. As one of India’s leading pharmaceutical companies, Lupin’s consistent results reinforce its standing as a respected and successful enterprise in the pharmaceutical industry.

USFDA Clears Lupin’s Generic Entresto, Poised to Challenge Novartis’ Top-Selling Medication

Lupin, an Indian pharmaceutical company, has received approval from the US Food and Drug Administration (USFDA) for its generic version of Entresto, a medication used to treat heart failure. Entresto, developed by Novartis, is a blockbuster drug that has generated significant revenue for the company. Lupin’s generic version of Entresto is expected to compete with Novartis’ bestseller in the US market.

Entresto is a combination of two medications, sacubitril and valsartan, which work together to reduce the risk of cardiovascular death and hospitalization in patients with heart failure. The drug was approved by the USFDA in 2015 and has since become a major revenue generator for Novartis.

Lupin’s generic version of Entresto, which is available in 24mg/200mg and 49mg/200mg strengths, is expected to be a significant competitor in the market. The company’s generic version has been approved under the 505(b)(2) pathway, which allows Lupin to market its generic version of Entresto without having to conduct expensive clinical trials.

The approval of Lupin’s generic Entresto is a significant milestone for the company, which has been expanding its presence in the US market. The company has a strong pipeline of generic and complex products, including a range of cardiovascular medications, which are expected to drive its growth in the coming years.

The approval of Lupin’s generic Entresto is also expected to benefit patients, who will have a more affordable option for treating heart failure. Heart failure is a chronic and debilitating condition that affects millions of people worldwide, and Entresto is an important medication for managing the condition.

In conclusion, Lupin’s generic Entresto has been approved by the USFDA, marking a significant milestone for the company. The approval is expected to drive growth for Lupin in the US market and provide patients with a more affordable option for treating heart failure. The company’s generic version of Entresto is expected to compete with Novartis’ bestseller, offering patients a lower-cost alternative for managing heart failure.

Lupin and Avast launch NaMuscla in Italy

Here is a 400-word summary of the content:

Lupin and Avas Pharmaceuticals SRL have announced the launch of NaMuscla (mexiletine) in Italy, an orphan drug approved for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. NDM disorders are a group of rare, inherited neuromuscular disorders characterized by the inability to relax muscles following voluntary contraction. NaMuscla has been shown to reduce myotonia symptoms, leading to significant improvements in quality of life and functional and clinical outcomes for patients.

The partnership with Avas will see the company commercialize NaMuscla as a Class C (Tier 2), while Lupin negotiates with AIFA (Agenzia Italiana del Farmaco) for the reimbursement of the product in Italy. This agreement ensures consistent access to NaMuscla for patients in Italy, leveraging the established supply network already serving patients in other European countries such as Germany, France, Spain, Austria, Norway, and the UK.

NaMuscla was designated an orphan drug and received EU marketing authorization in December 2018. The product is designed to treat myotonia, a hallmark symptom of NDM disorders, and can significantly improve the lives of patients with these rare and often debilitating conditions. The launch of NaMuscla in Italy marks an important step in making this innovative treatment accessible to patients across Europe.

The partnership between Lupin and Avas paves the way for patients to receive this life-changing treatment, which can greatly improve their quality of life and overall well-being. By working together, the two companies are committed to making a difference in the lives of patients with NDM disorders, ensuring they have access to the care and support they need to thrive.

In summary, the announcement marks a significant milestone in the fight against NDM disorders, with Avas and Lupin working together to bring NaMuscla to patients in Italy and beyond, providing hope and relief to those affected by these debilitating conditions.

Lupin’s heart failure therapy receives FDA approval following successful drug application

The US Food and Drug Administration (FDA) has approved Lupin’s abbreviated new drug application (ANDA) for its Sacubitril and Valsartan tablets for heart failure patients. The tablets are the generic equivalent of Novartis’ Entresto and are used to reduce cardiovascular risks in adults with chronic heart failure and decreased ejection fraction.

The approval covers dosages of 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg. Additionally, the tablets are also used to treat symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.

Lupin has also received tentative approval from the US Food and Drug Administration (FDA) under the US President’s Emergency Plan for AIDS Relief (PEPFAR) for its Abacavir, Dolutegravir, and Lamivudine tablets for oral suspension. This generic equivalent of ViiV Healthcare’s Triumeq PD tablets for oral suspension is set to be manufactured at Lupin’s Nagpur facility in India.

The company’s generic drugs are intended for distribution in low- and middle-income nations. The Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg fixed-dose combo is intended for the treatment of human immunodeficiency virus (HIV)-1 infection in children aged three and above weighing at least 6kg, and is a once-a-day single-pill regimen.

Lupin’s API Plus SBU head, global chief financial officer, and executive director Ramesh Swaminathan stated, “We are committed to providing affordable and high-quality treatments for patients worldwide. The tentative approval from the US FDA for our Abacavir, Dolutegravir, and Lamivudine tablets enables us to improve the well-being of pediatric patients with HIV-1, thereby significantly boosting our HIV medication portfolio.”

This news marks a significant milestone for Lupin, as it reinforces the company’s commitment to providing affordable and high-quality treatments for patients worldwide. The company is poised to tap into a market with annual US sales of $6.06 billion.

Lupin Manufacturing Solutions appoints Ajay Tiwari as Chief Human Resources Officer

Lupin Manufacturing Solutions, a leading provider of manufacturing solutions, has appointed Ajay Tiwari as its new Chief Human Resources Officer (CHRO). This appointment is a significant step forward for the company, as it looks to strengthen its HR function and drive business growth.

Ajay Tiwari brings over 20 years of experience in HR leadership roles, with a strong track record of building and leading high-performing teams. Prior to joining Lupin Manufacturing Solutions, he held senior HR positions at companies such as Accenture, IBM, and HCL Technologies. His expertise spans across various areas, including talent management, organizational design, and change management.

As CHRO, Tiwari will be responsible for leading the company’s HR function, which includes talent acquisition, employee engagement, learning and development, and organizational development. He will work closely with the leadership team to develop and implement HR strategies that align with the company’s business objectives.

Tiwari’s appointment is seen as a strategic move by Lupin Manufacturing Solutions to strengthen its HR capabilities and drive business growth. The company is expanding its operations globally, and Tiwari’s expertise will be crucial in building and leading a high-performing HR team that can support the company’s growth ambitions.

In a statement, the company’s CEO said, “We are thrilled to welcome Ajay to our leadership team. His extensive experience and expertise in HR will be invaluable in helping us build a strong and agile organization that can drive growth and innovation.”

Tiwari expressed his excitement about the new role, saying, “I am excited to join Lupin Manufacturing Solutions and contribute to the company’s growth and success. I am looking forward to working with the leadership team and HR team to build a high-performing organization that is agile, innovative, and customer-focused.”

Overall, Ajay Tiwari’s appointment as CHRO at Lupin Manufacturing Solutions is a significant development for the company, and his expertise will be crucial in driving business growth and success.

The pharma industry is likely to experience a slow pace of profit expansion in the third quarter.

Pharmaceutical companies in India are expected to experience slower profit growth in the October-December 2024 quarter compared to the previous two quarters. According to analysts, sales growth is projected to be around 10-12% and earnings before interest, taxes, depreciation, and amortisation (EBITDA) growth of 13-15%. The growth momentum is expected to slow down due to pricing pressures and a high base effect.

Large companies such as Dr Reddy’s Laboratories (DRL) and Sun Pharma are expected to contribute to the sales growth, with DRL projected to achieve over 10% growth in its India business. Mid-sized companies like JB Pharma, Torrent Pharma, and Mankind Pharma are likely to outperform with 11-13% year-on-year (YoY) growth, driven by their chronic portfolios.

In contrast, Cipla and Zydus are expected to report relatively weaker growth of 6-8% YoY due to supply constraints and base effects. The US generics segment is projected to remain flat due to price erosion and limited significant launches.

Overall, EBITDA is expected to grow by up to 15% YoY, but margins are expected to remain flat. Cipla and DRL are likely to face margin contraction, while Sun Pharma, Lupin, and Divi’s Laboratories are expected to report strong margin expansion.

The performance of key pharma players will be closely monitored by investors, particularly with respect to their outlook and commentary on margins. Updates on DRL approval timelines for large products in the US, Biocon’s outlook following the clearance of its facilities for biosimilars, and Aurobindo Pharma’s progress towards breakeven for its Penicillin G capacity will also be crucial.

India’s largest pharmaceutical company, Lupin, has emerged as a significant player.

The US Food and Drug Administration (FDA) has approved deuruxolitinib oral tablets (Leqselvi) to treat adults with severe alopecia areata, a chronic autoimmune disease that causes hair loss. The approval was made possible through two phase 3 clinical trials, THRIVE-AA1 and THRIVE-AA2, which showed that 29% to 32% of patients taking deuruxolitinib achieved at least 80% scalp hair coverage, compared to 1% of patients taking placebo. The drug is not recommended for use in combination with biologic immunomodulators, cyclosporine, JAK inhibitors, or potent immunosuppressants.

The recommended dosage of deuruxolitinib is 8 mg twice daily, and patients must be tested for CYP2C9 variants before starting treatment. Patients should also be screened for tuberculosis and viral hepatitis, and undergo a complete blood count check before initiating treatment. Deuruxolitinib carries a boxed warning for the risk of infections, mortality, and other serious side effects, and is contraindicated in patients who are CYP2C9 poor metabolizers.

The most common side effects of deuruxolitinib include acne, anemia, headache, fatigue, herpes, hyperlipidemia, increased weight, and neutropenia. Deuruxolitinib may cause fetal harm if used during pregnancy, and it is not recommended for use while breastfeeding or in patients with severe hepatic or renal impairment. Due to a patent dispute, the commercial launch of deuruxolitinib is indefinitely delayed.